4basebio plc is a Cambridge-based life sciences company quoted on London’s AIM market under the ticker 4BB (4BB.L on data platforms). It develops and manufactures synthetic DNA — and the nanoparticles used to deliver genetic payloads — for the next generation of genetic medicines …
AstraZeneca PLC is a UK-headquartered biopharmaceutical company and one of the largest constituents of the FTSE 100. It discovers, develops, manufactures and commercialises prescription medicines, with particular strength in oncology alongside meaningful franchises in cardiovascular, renal and metabolic disease, respiratory and immunology, and rare …
GSK plc, with corporate roots reaching back centuries, is a research-based biopharmaceutical company headquartered in the UK and employing roughly 67,000 people. It trades on the London Stock Exchange under the ticker GSK and operates through two broad segments: Commercial Operations and Total R&D.
Reckitt Benckiser Group plc is a FTSE 100 consumer-health and hygiene business headquartered in Slough. Its portfolio spans household names such as Dettol, Durex, Nurofen, Strepsils, Vanish, Gaviscon and Finish, alongside the Mead Johnson infant-nutrition brands including Enfamil.
Futura Medical plc attracted strong investor attention after its shares gained more than 13% during trading on 22 July 2026.
Ondine Biomedical Inc. (LSE:OBI) declined3.57% on 22 July 2026, reflecting the considerable volatility that can affect early-stage medical technology companies as investors balance significant commercial opportunities against funding requirements and execution risks.
Allergy Therapeutics PLC shares declined4.62% today (22 July 2026), placing the specialist biotechnology and allergy immunotherapy company among the notable London-listed decliners during the session. The weakness inLSE:AGYcomes as investors continue to evaluate clinical-development progress, commercial execution, funding requirements and the broader risk-reward profile …
Companies in the healthcare & diagnostics space are typically valued using metrics relevant to their business model and sector peers.
Companies in the healthcare & technology space are typically valued using metrics relevant to their business model and sector peers.
Companies in the healthcare & biotech space are typically valued using metrics relevant to their business model and sector peers.